Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo
- 19 February 2001
- journal article
- clinical trial
- Published by Elsevier in Journal of Immunological Methods
- Vol. 248 (1-2), 167-182
- https://doi.org/10.1016/s0022-1759(00)00350-1
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-FcγRI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neuJournal of Immunotherapy, 2001
- MECHANISMS OF PHAGOCYTOSIS IN MACROPHAGESAnnual Review of Immunology, 1999
- Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factorCancer Immunology, Immunotherapy, 1995
- Stability of HER-2/neu Expression Over Time and at Multiple Metastatic SitesJNCI Journal of the National Cancer Institute, 1993
- Human IgG Fc receptor heterogeneity: molecular aspects and clinical implicationsImmunology Today, 1993
- Redirected targeting of LDL to human monocyte Fc gamma receptors with bispecific antibodies.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Fc ReceptorsAnnual Review of Immunology, 1991
- Cytotoxicity mediated by human Fc receptors for IgGImmunology Today, 1989
- Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes.Journal of Clinical Investigation, 1983
- Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane.The Journal of Experimental Medicine, 1975